- "Will a Pill a Day Prevent HIV?" AIDS Vaccine Advocacy Coalition: The report examines the ethical issues surrounding the clinical testing of the antiretroviral drug tenofovir for HIV prevention, or pre-exposure prophylaxis. The report makes recommendations for ensuring that PREP trials are ethically conducted and calls for more coordination and planning among key stakeholders to accelerate the research (AVAC release, 3/24).
- "President's Emergency Plan for AIDS Relief First Annual Report to Congress," Department of State: The report, which tracks PEPFAR progress through September 2004, states that the "United States' rapid and strategically targeted deployment of resources has led to remarkable results." According to the report, PEPFAR in 2004 supported care for more than 1.7 million people affected by the disease and delivered HIV prevention messages to 120 million people (State Department release, 3/23).
- "Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection," AIDSinfo: HHS guidelines for the treatment of HIV-positive children have been updated to include the latest drug information, including pediatric dosing and new drug formulations (AIDSinfo, 3/24).
- "GENERATIONS: Strengthening Women and Families Affected by HIV/AIDS," National AIDS Fund, Johnson & Johnson: Under the terms of the new partnership, Johnson & Johnson will provide $1 million over two years to eight community-based organizations selected by NAF to address the needs of women and families whose lives have been impacted by HIV/AIDS (NAF release, 3/22).
Back to other news for March 25, 2005
Reprinted with permission from kaisernetwork.org. You can view the entire Kaiser Daily HIV/AIDS Report, search the archives, or sign up for email delivery at www.kaisernetwork.org/dailyreports/hiv. The Kaiser Daily HIV/AIDS Report is published for kaisernetwork.org, a free service of the Kaiser Family Foundation, by The Advisory Board Company. © 2004 by The Advisory Board Company and Kaiser Family Foundation. All rights reserved.